ARLINGTON, VA / ACCESSWIRE / October 11, 2016 / Fibrocell Science, Inc. (NASDAQ:FCSC) will be presenting at this year's The MicroCap Conference on October 24-25 in Philadelphia at the Hotel Monaco, along with 60 other companies in the microcap universe.
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.
This event is free for private and institutional investors - to learn more, please click here.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NASDAQ: FCSC) is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell's most advanced product candidate, FCX-007, has begun a Phase I/II trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third program in the research phase for the treatment of arthritis and related conditions. Fibrocell's gene-therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow us on Twitter at @Fibrocell.
SOURCE: Fibrocell Science, Inc.
ReleaseID: 446874
